Herpes simplex virus (HSV) is one of the causes of infectious blindness in Western countries, with no preventive vaccine available as of April 2025. The absence of a vaccine for HSV underscores the urgent need for innovative approaches that target reducing viral loads at the sites of transmission.
Recently, researchers from Penn Dental Medicine, in collaboration with colleagues in Finland, have addressed this issue in a study published in Molecular Therapy.
Read More
